Journal of Clinical Oncology
Articles in this Issue
SHR-A1811 as neoadjuvant therapy for HR-positive, HER2-low breast cancer: A single-arm, phase II clinical study.
594 Background: Human Epidermal Growth Factor Receptor ( HER2 ) -low breast cancer accounts for approximat...
Prognostic value of host genetic variants determining Bifidobacterium abundance in the lactose metabolism pathway for immunotherapy efficacy.
2651 Background: The potential predicative and therapeutic value of Bifidobacterium in immune checkpoint inhibitors (ICIs) treatme...
Diagnostic performance of <i>SHOX2</i> and <i>RASSF1A</i> gene methylation assays in malignant pleural effusion: A systematic review and meta-analysis.
e20058 Background: Malignant pleural effusion (MPE) is a common complication of advanced malignancies, often requiring palliative care. Differentiating MP...
Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic nasal cavity and paranasal sinus squamous-cell carcinoma: A prospective phase ll study.
6022 Background: Patients with recurrent or metastatic sinonasal squamous-cell carcinoma (R/M SNSCC) lack standardized systemic treatment protocols and pr...
Implementation of an automated dashboard to monitor unplanned reoperations in a public cancer hospital in São Paulo.
e23244 Background: Hospital Municipal Vila Santa Catarina (HMVSC), a public hospital in São Paulo affiliated with Hospital Israelita Albert Einstein, prov...
Effect of the combination of systemic and locoregional therapy on tumor recurrence and survival after liver transplantation for hepatocellular carcinoma (HCC).
4135 Background: Liver Transplantation (LT) results in the best survival in select HCC patients. Patients that do not meet transplant criteria based on tu...
Factors impacting treatment with abemaciclib + endocrine therapy in high risk early-stage HR+/HER2- breast cancer patients.
e12521 Background: The inhibitor of cyclin-dependent kinases 4 and 6, abemaciclib (abema), in combination with endocrine therapy (ET) is indicated for the...
Web-based analysis of multiparameter cytometry datasets.
e13687 Background: High-dimensional cytometry is pivotal in oncology research for detailed immune profiling. However, challenges in sample collection, pro...
Efficacy and safety of tislelizumab in combination with other chemotherapy agents in patients with biliary cancer: Systematic review and meta analysis.
e14618 Background: Biliary tract tumors (BTC) are rare but aggressive malignancies with poor prognoses and limited treatment choices. Despite advances in...
Prognostic significance of metaplasia in adenocarcinoma of the lung: A National Cancer Database analysis.
e20085 Background: Pulmonary adenocarcinoma is a major subtype of non-small cell lung cancer (NSCLC), yet the impact of metaplasia within the tumor remain...
ARTEMIDE-Lung03: A phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1.
TPS8653 Background: In the United States, non-squamous histology accounts for approximately 70% of all non-small-cell lung...
In-bedroom renewed air as anti-inflammatory adjuvant therapy in cancer survivors: BREATHS trial.
TPS12136 Background: Inflammation plays a pivotal role in both cancer progression and adverse cardiovascular (CV) effects of anticancer treatments. Cardio...
Phase 1, open-label, first-in-human study of ABBV-969, a dual variable antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer.
TPS5111 Background: Metastatic castration-resistant prostate cancer (mCRPC) is an incurable disease with high unmet need. Six-transmembrane epithelial ant...
Novel robotic navigation system for CT-guided lung ablation: First efficacy and safety evaluation.
e20070 Background: Microwave ablation is a widely used technique for treating solid tumors. MWA focuses energy to minimize damage to surrounding tissues,...
Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a phase 1/2 study.
6561 Background: Myeloablative conditioning for allogeneic stem cell transplant (allo-SCT) can be given safely to older patients by extending the duration...
Can lymph node next-generation sequencing assist in better predicting the prognosis of lung adenocarcinoma?
e15063 Background: Despite TNM staging, early-staged lung cancer patients are not exempt from the risks of recurrence or lymphatic spread. Next-generation...
A single-arm IIT study of HA131 (hepatic arterial infusion) in combination with systemic therapy (XELOX with or without bevacizumab) as first-Line treatment in gastrointestinal cancer with liver metastases.
e15546 Background: Hepatic arterial infusion chemotherapy (HAIC) combined with systemic therapy could be more effective in controlling the progression of...
Comparison of survival between liver-only metastasis and other metastatic sites in patients with de novo stage 4 gastric cancer: Nationwide data from a single institute.
e16044 Background: Although recent studies have shown a steady decline in the incidence and mortality over the past several decades, Gastric cancer (GC) r...
Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.
TPS3160 Background: Mesothelin (MSLN) is a membrane glycoprotein overexpressed in several solid tumors, making it a promising target for cancer treatments...
Cardiovascular risks associated with aromatase inhibitors versus tamoxifen in breast cancer: A systematic review and meta-analysis.
12018 Background: Aromatase inhibitors (AIs), such as anastrozole, letrozole, and exemestane, are commonly used in the treatment of women with early or ad...
Positron-emission tomography utility for progression-free survival prediction in HER2-positive advanced breast cancer patients treated with pertuzumab, trastuzumab, and docetaxel.
e13012 Background: Pertuzumab, trastuzumab, and docetaxel (TPH) remain the gold standard for first-line therapy in patients with HER2-positive advanced br...
Real-world safety and efficacy of tarlatamab in patients with small cell lung cancer or extrapulmonary small cell carcinoma.
e20127 Background: Small cell lung cancer (SCLC) remains the most aggressive lung cancer with poor prognosis. Tarlatamab (T), a bi-specific T-cell engager...
The 31-gene expression profile as a guide to better risk-aligned care decisions for patients with stage I–III cutaneous melanoma: An NCI-SEER analysis.
9573 Background: Current management guidelines for cutaneous melanoma (CM) are based on AJCC staging to stratify patients into risk groups. However, this...
Cardiovascular adverse events in multiple myeloma patients: A comparative study analysis of daratumumab vs. lenalidomide.
e19550 Background: Advances in treatment strategies in multiple myeloma (MM) have significantly improved life expectancy and progression-free survival. Ho...
Initial results from a first-in-human phase 1 study of LY4170156, an ADC targeting folate receptor alpha (FRα), in advanced ovarian cancer and other solid tumors.
3023 Background: Folate receptor alpha (FRα) is overexpressed in several solid tumors. LY4170156 is an Fc-silent, FRα specific humanized IgG1 ADC linked t...